Merck has invested €35m in biosafety testing at its Glasgow and Stirling sites, creating nearly 500 new jobs and bringing its workforce to more than 1,200 across the two sites.
The centrepiece of the investment is a new 1,200 sq m facility in Glasgow, which will house molecular biology and sequencing services.
The company will expand testing capacity in its current buildings with biosafety testing, analytical development and viral clearance suites.